Literature DB >> 18030317

Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension.

M F L Meijs1, M L Bots, E-J A Vonken, M-J M Cramer, P G Melman, B K Velthuis, Y van der Graaf, W P Th M Mali, P A Doevendans.   

Abstract

Left ventricular hypertrophy (LVH) is an independent risk factor for the development of heart failure, coronary heart disease and stroke. LVH develops in response to haemodynamic overload, e.g. hypertension. LVH was originally thought to start as an adaptive and beneficial response required to normalise wall stress. However, this concept has been challenged by recent animal experiments suggesting that any degree of LVH is detrimental for the preservation of cardiac function and survival. If confirmed in humans, these findings imply that an increase in LV mass should be prevented, e.g. by lifestyle or pharmacological interventions. To facilitate and optimise interventions, the SMART Heart study was recently set up to develop a prediction model, also involving single nucleotide polymorphism data, for the identification of subjects at high risk of developing LVH in hypertension. For this purpose 1000 subjects with chronic hypertension will undergo cardiac MR imaging. In addition, this study allows the extrapolation of animal experimental genetic research into the human situation. (Neth Heart J 2007;15:295-8.).

Entities:  

Keywords:  MRI; delayed enhancement; hypertrophy; risk prediction; single nucleotide polymorphism (SNP)

Year:  2007        PMID: 18030317      PMCID: PMC1995099          DOI: 10.1007/BF03086003

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  26 in total

Review 1.  Technology insight: assessment of myocardial viability by delayed-enhancement magnetic resonance imaging.

Authors:  Robert M Judd; Anja Wagner; Wolfgang G Rehwald; Timothy Albert; Raymond J Kim
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-03

Review 2.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies.

Authors:  Heiko Mahrholdt; Anja Wagner; Robert M Judd; Udo Sechtem; Raymond J Kim
Journal:  Eur Heart J       Date:  2005-04-14       Impact factor: 29.983

3.  Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: The Hypertension Genetic Epidemiology Network (HyperGEN) Study.

Authors:  R B Devereux; J N Bella; V Palmieri; A Oberman; D W Kitzman; P N Hopkins; D C Rao; D Morgan; M Paranicas; D Fishman; D K Arnett
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

Review 4.  Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography.

Authors:  Jae K Oh; Liv Hatle; A Jamil Tajik; William C Little
Journal:  J Am Coll Cardiol       Date:  2006-01-18       Impact factor: 24.094

5.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

6.  Second manifestations of ARTerial disease (SMART) study: rationale and design.

Authors:  P C Simons; A Algra; M F van de Laak; D E Grobbee; Y van der Graaf
Journal:  Eur J Epidemiol       Date:  1999-10       Impact factor: 8.082

7.  MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure.

Authors:  Ralph J van Oort; Eva van Rooij; Meriem Bourajjaj; Joost Schimmel; Maurits A Jansen; Roel van der Nagel; Pieter A Doevendans; Michael D Schneider; Cees J A van Echteld; Leon J De Windt
Journal:  Circulation       Date:  2006-07-17       Impact factor: 29.690

8.  MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction.

Authors:  Eva van Rooij; Pieter A Doevendans; Harry J G M Crijns; Sylvia Heeneman; Daniel J Lips; Marc van Bilsen; R Sanders Williams; Eric N Olson; Rhonda Bassel-Duby; Beverly A Rothermel; Leon J De Windt
Journal:  Circ Res       Date:  2004-01-22       Impact factor: 17.367

9.  Prognosis of left ventricular geometric patterns in the Framingham Heart Study.

Authors:  H M Krumholz; M Larson; D Levy
Journal:  J Am Coll Cardiol       Date:  1995-03-15       Impact factor: 24.094

10.  Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study.

Authors:  W B Kannel; D Levy; L A Cupples
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  3 in total

1.  Left ventricular mass assessment by CMR; how to define the optimal index.

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-06       Impact factor: 2.357

2.  Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension.

Authors:  M F L Meijs; M L Bots; E-J A Vonken; M-J M Cramer; P G Melman; B K Velthuis; Y van der Graaf; W P Th M Mali; P A Doevendans
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

3.  Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rats.

Authors:  Jacqueline N Minas; Max A Thorwald; Debra Conte; Jose-Pablo Vázquez-Medina; Akira Nishiyama; Rudy M Ortiz
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-11       Impact factor: 2.557

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.